A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
Status:
Terminated
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary
purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and
pharmacodynamics of multiple doses of PF-03882845 in this population.